Vantictumab
As of the edition of 20 October 2026, Vantictumab is an antibody: went quiet in 2017; acts on FZD1, FZD2 and FZD5 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2017
- Kind
- Antibody
- Registered trials
- 4, 0 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product5 company-target rows are on route A because of Vantictumab.
See the 5 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Mereo BioPharma | Lead sponsor of trials | 2011 to now |